Evidence map›Paper›PMID 39680494›Full record

ArticleJournal of neurochemistry2025

Testing cognitive normal for Alzheimer's disease prediction.

Jie Meng, Peng Lei

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jie MengDepartment of Geriatrics and State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Peng LeiDepartment of Neurology and State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.ORCID 0000-0001-5652-1962

Funding

Major Science & Technology Program of Sichuan Province 2022ZDZX0021Sichuan Science and Technology Program 2024YFHZ0010STI2030 Major Projects 2023ZD0507200West China Hospital 1.3.5 Project for Disciplines of Excellence ZYYC23016
6 · The paper itself

Abstract

One standing challenge for Alzheimer's disease (AD) research is early diagnosis, which provides a time window for early intervention. Sharmin et al recently reported a positive association between plasma ptau181 and plasma metabolites, medium- and long-chain acylcarnitines (ACs) in both cognitively normal (CN) Aβ- and CN Aβ+ older adults, suggesting a link between initial Aβ pathology and acylcarnitine-mediated energy metabolism pathways. Consistently, ACs could classify PET-Aβ status in elderly individuals. This study has provided further clues for early biomarker searching for AD, linking metabolic pathways with AD pathogenesis.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersCarnitineCognitionEarly DiagnosisHumansPositron-Emission TomographyPredictive Value of TestsacylcarnitineAmyloid beta-PeptidesBiomarkersCarnitineAlzheimer's diseaseAβ pathologymedium‐ and long‐chain acylcarnitinesplasma ptau181

Identifiers

PMID39680494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.